Indiana University School of Public Health-Bloomington, Bloomington, IN, United States.
University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, United States.
JMIR Res Protoc. 2024 Sep 9;13:e60621. doi: 10.2196/60621.
This study will pilot-test the mobile app, Medication Safety @HOME-Meds@HOME intervention to improve medication administration accuracy, reduce preventable adverse drug events, and ultimately improve chronic care management for children with medical complexity (CMC). The Meds@HOME app was co-designed with CMC families, secondary caregivers (SCGs), and health professionals to support medication management for primary caregivers (PCGs) and SCGs of CMC. We hypothesize that Meds@HOME will improve caregivers' medication administration accuracy, reduce preventable adverse drug events, and ultimately improve chronic care management.
This study aims to evaluate the effectiveness of Meds@HOME on medication administration accuracy for PCGs and SCGs.
This study will recruit up to 152 PCGs and 304 SCGs of CMC who are prescribed at least 1 scheduled high-risk medication and receive care at the University of Wisconsin American Family Children's Hospital. PCGs will be randomly assigned, for the 6-month trial, to either the control group (not trialing Meds@HOME) or the intervention group (trialing Meds@HOME) using 1:1 ratio. The Meds@HOME app allows caregivers to create a child profile, store medication and care instructions, and receive reminders for upcoming and overdue care routines and medication refills. Surveys completed both at the start and end of the trial measure demographics, medication delivery knowledge, confidence in the CMC's caregiving network, and comfort with medical information. Univariate and multivariate generalized estimation equations will be used for primary statistical analysis. The primary outcome is the PCG's rate of medication administration accuracy measured as correct identification of each of the following for a randomly selected high-risk medication: indication, formulation, dose, frequency, and route at baseline and after 6 months. Secondary outcomes include SCG medication administration accuracy (indication, formulation, dose, frequency, and route), count of University of Wisconsin hospital and emergency department encounters, PCG-reported medication adherence, count of deaths, and PCG medication confidence and understanding.
Recruitment for this study began on November 29, 2023. As of May 15, 2024, we have enrolled 94/152 (62%) PCGs. We expect recruitment to end by August 1, 2024, and the final participant will complete the study by January 28, 2025, at which point we will start analyzing the complete responses. We expect publication of results at the end of 2025.
The Meds@HOME mobile app provides a promising strategy for improving PCG medication safety for CMC who take high-risk medications. In addition, this protocol highlights novel procedures for recruiting SCGs of CMC. In the future, this app could be used more broadly across diverse caregiving networks to navigate complex medication routines and promote medication safety.
ClinicalTrials.gov NCT05816590; https://clinicaltrials.gov/study/NCT05816590.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/60621.
本研究将对移动应用程序 Medication Safety@HOME-Meds@HOME 进行试点测试,以提高药物管理的准确性,减少可预防的药物不良事件,并最终改善患有复杂医疗需求的儿童(CMC)的慢性病管理。Meds@HOME 应用程序是与 CMC 家庭、二级照顾者(SCG)和卫生专业人员共同设计的,旨在为 CMC 的主要照顾者(PCG)和 SCG 提供药物管理支持。我们假设 Meds@HOME 将提高照顾者的药物管理准确性,减少可预防的药物不良事件,并最终改善慢性病管理。
本研究旨在评估 Meds@HOME 对 PCG 和 SCG 药物管理准确性的影响。
本研究将招募最多 152 名 PCG 和 304 名 CMC 的 SCG,他们至少服用 1 种规定的高风险药物,并在威斯康星大学美国家族儿童医院接受治疗。PCG 将采用 1:1 比例的随机分组,在 6 个月的试验中被分配到对照组(不试用 Meds@HOME)或干预组(试用 Meds@HOME)。Meds@HOME 应用程序允许照顾者创建儿童档案、存储药物和护理说明,并接收即将到来和逾期的护理程序和药物补充的提醒。在试验开始和结束时完成的调查测量人口统计学、药物输送知识、对 CMC 护理网络的信心以及对医疗信息的舒适度。单变量和多变量广义估计方程将用于主要的统计分析。主要结果是 PCG 的药物管理准确性率,以随机选择的高风险药物的以下每个方面的正确识别来衡量:指征、剂型、剂量、频率和途径,基线和 6 个月后。次要结果包括 SCG 的药物管理准确性(指征、剂型、剂量、频率和途径)、威斯康星大学医院和急诊部门就诊次数、PCG 报告的药物依从性、死亡人数以及 PCG 对药物的信心和理解。
本研究于 2023 年 11 月 29 日开始招募。截至 2024 年 5 月 15 日,我们已招募了 94/152(62%)名 PCG。我们预计招募工作将在 2024 年 8 月 1 日结束,最后一名参与者将在 2025 年 1 月 28 日完成研究,届时我们将开始分析完整的回复。我们预计在 2025 年底公布结果。
Meds@HOME 移动应用程序为服用高风险药物的 CMC 的 PCG 提供了一种有前途的药物安全策略。此外,本方案强调了招募 CMC 的 SCG 的新程序。未来,该应用程序可以更广泛地用于各种护理网络,以管理复杂的药物常规并促进药物安全。
ClinicalTrials.gov NCT05816590;https://clinicaltrials.gov/study/NCT05816590。
国际注册报告标识符(IRRID):DERR1-10.2196/60621。